

GLAXOSMITHKLINE PLC  
Form 6-K  
May 11, 2011

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending May 2011

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--



BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 11 May 2011

Name of applicant: GlaxoSmithKline plc  
Name of scheme: GlaxoSmithKline Share Option Plan - Ordinary Shares

Period of return: From: 1 November 2010 To: 30 April 2011

Balance of unallotted securities under scheme(s) from previous return: 2,092,426

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 832,235

Equals: Balance under scheme(s) not yet issued/allotted at end of period: 1,260,191

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 11 May 2011

Name of applicant:	GlaxoSmithKline plc		
Name of scheme:	GlaxoSmithKline Share Option Plan - ADS		
Period of return:	From:	1 November 2010	To: 30 April 2011
Balance of unallotted securities under scheme(s) from previous return:	4,007,856		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	0		
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	1,555,344		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	2,452,512		

Name of contact:	Victoria Whyte
Telephone number of contact:	020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 11 May 2011

Name of applicant: GlaxoSmithKline plc  
Name of scheme: Glaxo Wellcome UK Share Option Scheme  
Period of return: From: 1 November 2010 To: 30 April 2011

Balance of unallotted securities under scheme(s) from previous return: 5,119,750

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0

Equals: Balance under scheme(s) not yet issued/allotted at end of period: 5,119,750

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000



BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 11 May 2011

Name of applicant:	GlaxoSmithKline plc		
Name of scheme:	Glaxo Wellcome International Share Option Scheme		
Period of return:	From:	1 November 2010	To: 30 April 2011
Balance of unallotted securities under scheme(s) from previous return:	13,267,156		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	0		
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	0		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	13,267,156		

Name of contact:	Victoria Whyte
Telephone number of contact:	020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 11 May 2011

Name of applicant: GlaxoSmithKline plc  
Name of scheme: Glaxo Wellcome 1999 Share Option Plan  
Period of return: From: 1 November 2010 To: 30 April 2011

Balance of unallotted securities under scheme(s) from previous return: 1,040,000

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0

Equals: Balance under scheme(s) not yet issued/allotted at end of period: 1,040,000

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000



BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 11 May 2011

Name of applicant: GlaxoSmithKline plc  
Name of scheme: SmithKline Beecham 1989 Executive Share  
Option Plan - Approved - Ordinary Shares  
Period of return: From: 1 November 2010 To: 30 April 2011

Balance of unallotted securities under scheme(s)  
from previous return: 163,606

Plus: The amount by which the block scheme(s)  
has been increased since the date of the last  
return (if any increase has been applied for): 0

Less: Number of securities issued/allotted under  
scheme(s) during period (see LR3.5.7G): 0

Equals: Balance under scheme(s) not yet  
issued/allotted at end of period: 163,606

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 11 May 2011

Name of applicant: GlaxoSmithKline plc  
Name of scheme: SmithKline Beecham 1989 Executive Share  
Option Plan - Unapproved - ADS  
Period of return: From: 1 November 2010 To: 30 April 2011

Balance of unallotted securities under scheme(s)  
from previous return: 275,420

Plus: The amount by which the block scheme(s)  
has been increased since the date of the last  
return (if any increase has been applied for): 0

Less: Number of securities issued/allotted under  
scheme(s) during period (see LR3.5.7G): 0

Equals: Balance under scheme(s) not yet  
issued/allotted at end of period: 275,420

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 11 May 2011

Name of applicant: GlaxoSmithKline plc  
Name of scheme: SmithKline Beecham 1989 Executive Share  
Option Plan - Unapproved - Ordinary  
Period of return: From: 1 November 2010 To: 30 May 2011

Balance of unallotted securities under scheme(s)  
from previous return: 100,000

Plus: The amount by which the block scheme(s)  
has been increased since the date of the last  
return (if any increase has been applied for): 0

Less: Number of securities issued/allotted under  
scheme(s) during period (see LR3.5.7G): 0

Equals: Balance under scheme(s) not yet  
issued/allotted at end of period: 100,000

Name of contact: Victoria Whyte  
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 11 May 2011

Name of applicant:	GlaxoSmithKline plc		
Name of scheme:	GlaxoSmithKline Savings Related Share Option Scheme		
Period of return:	From:	1 November 2010	To: 30 April 2011
Balance of unallotted securities under scheme(s) from previous return:	4,263,507		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	0		
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	1,172,784		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	3,090,723		

Name of contact:	Victoria Whyte
Telephone number of contact:	020 8047 5000

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: May 11, 2011

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc